Subscribe Now Subscribe Today
Science Alert
 
Blue
   
Curve Top
Pakistan Journal of Biological Sciences
  Year: 2005 | Volume: 8 | Issue: 9 | Page No.: 1256-1260
DOI: 10.3923/pjbs.2005.1256.1260
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Evaluation of Methods for Detection of Clostridium difficile and its Toxins in Patients with Nosocomial Diarrhoea

N. Sadeghifard , M.H. Salari , M.R. Ghasemi and F. Amin-Harati

Abstract:
The aim of this study was to compare stool cytotoxin assay as the standard test with enzyme immunoassay system (C. difficile Tox A/B Tech Lab) and C. difficile bacterial culture on cycloserine-cefoxitin fructose agar followed by cytotoxin assay (toxigenic culture). A total of 650 stool specimens from hospitalized patients with nosocomial diarrhoea were collected from December 2002 to February 2004. C. difficile was detected by culture method in 146 samples. Of these samples 103 isolates were toxigenic by toxigenic culture. One hundred twelve and 108 stool specimens were positive for C. difficile toxins by enzyme immunoassay (Tox A/B immunoassay) and stool cytotoxin assay, respectively. Ninety eight samples were diagnosed to be positive in all test methods. Toxigenic C. difficile was isolated from 2 stool cytotoxin assay and 3 enzyme immunoassay negative stools. Sensitivity and specificity for Tox A/B immunoassay in relation to the stool cytotoxin assay was 95.6% (95% CI) and 98.3% (95% CI), respectively. The results of the present study showed that sensitivity and specificity Tox A/B immunoassay was very close with stool cytotoxin assay.
PDF References Citation Report Citation
How to cite this article:

N. Sadeghifard , M.H. Salari , M.R. Ghasemi and F. Amin-Harati , 2005. Evaluation of Methods for Detection of Clostridium difficile and its Toxins in Patients with Nosocomial Diarrhoea. Pakistan Journal of Biological Sciences, 8: 1256-1260.

DOI: 10.3923/pjbs.2005.1256.1260

URL: https://scialert.net/abstract/?doi=pjbs.2005.1256.1260

COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 

Curve Bottom